phreesia - PHR
PHR
Close Chg Chg %
16.34 0.18 1.10%
Open Market
16.52
+0.18 (1.10%)
Volume: 695.63K
Last Updated:
Dec 17, 2025, 1:20 PM EDT
Company Overview: phreesia - PHR
PHR Key Data
| Open $16.30 | Day Range 16.24 - 16.74 |
| 52 Week Range 15.41 - 32.76 | Market Cap $985.69M |
| Shares Outstanding 60.29M | Public Float 55.46M |
| Beta 0.64 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.09 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.88M |
PHR Performance
| 1 Week | 0.62% | ||
| 1 Month | -18.45% | ||
| 3 Months | -31.50% | ||
| 1 Year | -35.02% | ||
| 5 Years | -70.09% |
PHR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
18
Full Ratings ➔
About phreesia - PHR
Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.
PHR At a Glance
Phreesia, Inc.
1521 Concord Pike
Wilmington, Delaware 19803
| Phone | 1-888-654-7473 | Revenue | 419.81M | |
| Industry | Packaged Software | Net Income | -58,527,000.00 | |
| Sector | Technology Services | 2025 Sales Growth | 17.826% | |
| Fiscal Year-end | 01 / 2026 | Employees | 2,082 | |
| View SEC Filings |
PHR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.904 |
| Price to Book Ratio | 6.312 |
| Price to Cash Flow Ratio | 50.85 |
| Enterprise Value to EBITDA | -62.182 |
| Enterprise Value to Sales | 3.746 |
| Total Debt to Enterprise Value | 0.011 |
PHR Efficiency
| Revenue/Employee | 201,639.289 |
| Income Per Employee | -28,110.951 |
| Receivables Turnover | 5.703 |
| Total Asset Turnover | 1.105 |
PHR Liquidity
| Current Ratio | 1.779 |
| Quick Ratio | 1.779 |
| Cash Ratio | 0.739 |
PHR Profitability
| Gross Margin | 60.784 |
| Operating Margin | -13.099 |
| Pretax Margin | -13.294 |
| Net Margin | -13.941 |
| Return on Assets | -15.41 |
| Return on Equity | -22.674 |
| Return on Total Capital | -20.709 |
| Return on Invested Capital | -22.061 |
PHR Capital Structure
| Total Debt to Total Equity | 6.723 |
| Total Debt to Total Capital | 6.299 |
| Total Debt to Total Assets | 4.582 |
| Long-Term Debt to Equity | 3.322 |
| Long-Term Debt to Total Capital | 3.112 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Phreesia - PHR
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 213.23M | 280.91M | 356.30M | 419.81M | |
Sales Growth
| +43.42% | +31.74% | +26.84% | +17.83% | |
Cost of Goods Sold (COGS) incl D&A
| 105.91M | 138.03M | 154.55M | 164.63M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 24.52M | 28.77M | 30.54M | 29.70M | |
Depreciation
| 15.99M | 19.76M | 17.58M | 14.18M | |
Amortization of Intangibles
| 6.32M | 7.32M | 11.90M | 13.70M | |
COGS Growth
| +50.61% | +30.34% | +11.97% | +6.52% | |
Gross Income
| 107.33M | 142.88M | 201.75M | 255.18M | |
Gross Income Growth
| +36.97% | +33.12% | +41.20% | +26.49% | |
Gross Profit Margin
| +50.33% | +50.86% | +56.62% | +60.78% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 223.17M | 319.43M | 335.12M | 310.17M | |
Research & Development
| 52.27M | 91.24M | 112.35M | 117.36M | |
Other SG&A
| 170.90M | 228.18M | 222.77M | 192.81M | |
SGA Growth
| +115.25% | +43.13% | +4.91% | -7.44% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 978.00K | 4.22M | 761.00K | |
EBIT after Unusual Expense
| (116.82M) | (176.55M) | (137.60M) | (55.75M) | |
Non Operating Income/Expense
| 1.00K | 2.30M | 4.11M | 2.29M | |
Non-Operating Interest Income
| 79.00K | 2.48M | 4.07M | 2.68M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.16M | 1.41M | 1.85M | 2.35M | |
Interest Expense Growth
| -31.39% | +21.32% | +31.40% | +26.59% | |
Gross Interest Expense
| 1.16M | 1.41M | 1.85M | 2.35M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (117.98M) | (175.66M) | (135.34M) | (55.81M) | |
Pretax Income Growth
| -333.06% | -48.89% | +22.95% | +58.76% | |
Pretax Margin
| -55.33% | -62.53% | -37.99% | -13.29% | |
Income Tax
| 182.00K | 483.00K | 1.54M | 2.72M | |
Income Tax - Current - Domestic
| 39.00K | 49.00K | 76.00K | 102.00K | |
Income Tax - Current - Foreign
| - | - | 1.24M | 2.40M | - |
Income Tax - Deferred - Domestic
| - | 109.00K | 38.00K | 214.00K | |
Income Tax - Deferred - Foreign
| - | 143.00K | 325.00K | 190.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (118.16M) | (176.15M) | (136.88M) | (58.53M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (118.16M) | (176.15M) | (136.88M) | (58.53M) | |
Net Income Growth
| -332.95% | -49.07% | +22.29% | +57.24% | |
Net Margin Growth
| -55.41% | -62.71% | -38.42% | -13.94% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (118.16M) | (176.15M) | (136.88M) | (58.53M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (118.16M) | (176.15M) | (136.88M) | (58.53M) | |
EPS (Basic)
| -2.3685 | -3.359 | -2.5088 | -1.0163 | |
EPS (Basic) Growth
| -242.96% | -41.82% | +25.31% | +59.49% | |
Basic Shares Outstanding
| 49.89M | 52.44M | 54.56M | 57.59M | |
EPS (Diluted)
| -2.3685 | -3.359 | -2.5088 | -1.0163 | |
EPS (Diluted) Growth
| -242.96% | -41.82% | +25.31% | +59.49% | |
Diluted Shares Outstanding
| 49.89M | 52.44M | 54.56M | 57.59M | |
EBITDA
| (91.32M) | (147.78M) | (102.83M) | (25.29M) | |
EBITDA Growth
| -1,136.59% | -61.83% | +30.42% | +75.41% | |
EBITDA Margin
| -42.83% | -52.61% | -28.86% | -6.02% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 29.941 | |
| Number of Ratings | 18 | Current Quarters Estimate | 0.061 | |
| FY Report Date | 01 / 2026 | Current Year's Estimate | 0.077 | |
| Last Quarter’s Earnings | 0.07 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.02 | Next Fiscal Year Estimate | 0.49 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 9 | 12 | 12 |
| Mean Estimate | 0.06 | 0.09 | 0.08 | 0.49 |
| High Estimates | 0.19 | 0.17 | 0.20 | 0.77 |
| Low Estimate | -0.01 | 0.04 | 0.01 | 0.29 |
| Coefficient of Variance | 81.73 | 41.21 | 63.77 | 29.77 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 15 | 15 | 13 |
| OVERWEIGHT | 3 | 2 | 2 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Phreesia - PHR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Phreesia - PHR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 18, 2025 | Balaji Gandhi Chief Financial Officer | 107,547 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share | 2,560,694.07 |
| Apr 18, 2025 | Allison C. Hoffman General Counsel & Secretary | 137,921 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share | 3,283,899.01 |
| Apr 18, 2025 | Chaim Indig Chief Executive Officer; Director | 1,254,574 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share | 29,871,406.94 |
| Apr 18, 2025 | Evan Roberts Chief Operating Officer | 774,807 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share | 18,448,154.67 |
| Apr 18, 2025 | Amy Beth VanDuyn SVP, Human Resources | 129,820 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share | 3,091,014.20 |
| Apr 18, 2025 | David Linetsky SVP, Life Sciences | 219,727 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share | 5,231,699.87 |
| Apr 18, 2025 | David Linetsky SVP, Life Sciences | 217,239 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.66 per share | 5,139,874.74 |
| Apr 18, 2025 | Yvonne Hui Principal Accounting Officer | 25,333 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.04 per share | 609,005.32 |
| Apr 18, 2025 | Yvonne Hui Principal Accounting Officer | 24,915 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.66 per share | 589,488.90 |
| Apr 9, 2025 | David Linetsky SVP, Life Sciences | 9,260 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | David Linetsky SVP, Life Sciences | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 21, 2025 | Balaji Gandhi Chief Financial Officer | 105,418 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30 per share | 3,162,540.00 |
| Feb 21, 2025 | Evan Roberts Chief Operating Officer | 741,020 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30 per share | 22,230,600.00 |